395 results about "Donor cell" patented technology

An improved method of nuclear transfer involving the transplantation of donor differentiated cell nuclei into enucleated oocytes of the same species as the donor cell is provided. The resultant nuclear transfer units are useful for multiplication of genotypes and transgenic genotypes by the production of fetuses and offspring, and for production of isogenic CICM cells, including human isogenic embryonic or stem cells. Production of genetically engineered or transgenic mammalian embryos, fetuses and offspring is facilitated by the present method since the differentiated cell source of the donor nuclei can be genetically modified and clonally propagated.

Various methods for providing relay node priority are provided. One example method includes generating a relay node access message for initiating an access procedure to establish a connection between a relay node and a donor cell. The relay node access message may be generated in accordance with an access priority scheme. The access priority scheme may be defined such that a higher priority is allocated to the relay node access message than a user device access message for initiating the access procedure to establish a direct connection between the user device and the donor cell. The example method may also include providing for transmission of the relay node access message in accordance with the access priority scheme. Similar and related example methods and example apparatuses are also provided.

The intervertebral disc is avascular. With aging, endplates become occluded by calcified layers, and diffusion of nutrients and oxygen into the disc diminishes. The disc degenerates, and pain ensues. Conduits are delivered and deployed into the intervertebral disc to re-establish the exchange of nutrients and waste between the disc and bodily circulation to stop or reverse disc degeneration and relieve pain. The intervertebral disc installed with semi-permeable conduits may be used as an immuno-isolated capsule to encapsulate donor cells capable of biosynthesizing therapeutic molecules. The semi-permeable conduits establish the exchange of nutrients and therapeutic molecules between disc and bodily circulation to treat a disease without using immuno-suppressive drugs.

Contemplated compositions and methods are directed to the use of microvesicles from an optionally recombinant donor cell to impart a desirable effect to a recipient cell. In certain preferred aspects, RNA of the microvesicles is employed to achieve the desirable effect. For example, microvesicles are used in vitro to increase the number of passages of a cell growing in a medium, reduce serum and/or growth factor requirements of a cell growing in a medium, and/or delay differentiation of a cell growing in a medium. Further preferred aspects include use of the microvesicles as therapeutic agents in which RNA, a membrane protein, and/or a cytosolic protein encapsulated in or coupled to the microvesicle provide a therapeutic effect. Additionally, diagnostic methods are contemplated in which RNA of a microvesicle isolated from a mammal is associated with a condition of the mammal.

The present invention relates to the use of a non-lethal preparative regimen for the treatment of a patient with human immunodeficiency virus (HIV) disease. In a clinical trial, an HIV-positive patient was conditioned by non-lethal doses of irradiation and a chemotherapeutic drug prior to receiving donor bone marrow cells from a baboon. While long-term engraftment of donor cells was not observed, the non-lethal preparative conditioning regimen was able to reduce the viral burden and improved the clinical outcome. Such method is useful for treatment of patients with advanced acquired immunodeficiency syndrome (AIDS).

A system for balancing charge within a battery pack with a plurality of cells connected in series, including a capacitor; a processor configured to select a combination of donor cells and receiver cells from the plurality of cells in one of the following two modes: (1) a first mode where the number of donor cells is equal to the number of receiver cells, and (2) a second mode where the number of donor cells is greater than the number of receiver cells; and a plurality of switches that electrically connect the capacitor to the donor cells to charge the capacitor, and that electrically connected the capacitor to the receiver cells to discharge the capacitor. The transfer of charge between cells in the plurality of cells through the capacitor balances the charge within the battery pack.

The invention provides an overexpression porcine co-stimulatory 4-1BB vector and application thereof. PCR (polymerase chain reaction) amplification is performed on a left homologous arm and a right homologous arm of an intron 1 of a rosa26 gene, a 4-1BB regulatory sequence and an OCT4 specific promoter; the left homologous arm, a 4-1BB expression cassette, LoxP locus-contained Cre and Neo expression cassettes, the right homologous arm and negative selection DTA diphtheria toxin are connected in sequence to obtain a 4-1BB homologous recombinant vector p4BOCNDR; the vector and a CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated) targeting vector of sgRNA (small guide ribonucleic acid) containing the intron 1 of the specific targeting porcine rosa26 gene are transferred together into a porcine fetus fibroblast; by taking a positive cell as a donor cell and an oocyte as a recipient cell, a cloned embryo is obtained through a somatic cell nuclear transfer technique; the cloned embryo is transplanted into a porcine uterus for fetation to obtain a transgenic pig integrating a 4-1BB gene at the fixed point of a first intron of the rosa26 gene and automatically deleting a marker gene.

An improved method of nuclear transfer involving the transplantation of donor cell nuclei into enucleated oocytes of a species different from the donor cell is provided. The resultant nuclear transfer units are useful for the production of isogenic embryonic stem cells, in particular human isogenic embryonic or stem cells. These embryonic or stem-like cells are useful for producing desired differentiated cells and for introduction, removal or modification, of desired genes, e.g., at specific sites of the genome of such cells by homologous recombination. These cells, which may contain a heterologous gene, are especially useful in cell transplantation therapies and for in vitro study of cell differentiation.

The present invention relates to a device and method for implanting hair follicle-inducing cells within the scalp. The hair follicle cells are generated by the use of tissue culture process from autologous donor cells. The cells are placed upon a microprojection array for implantation within the scalp utilizing predetermined parameters of angle, density and depth.

The invention provides a targeted sgRNA for editing a pig APN gene and a modified carrier as well as a preparation method and application thereof, and relates to the technical field of gene engineering. The sgRNA and the gene modified carrier provided by the invention are strong in speciality, and effectively edit the pig APN gene on cell level by a CRISPR/Cas9n system, and positive cells are edited by the obtained APN gene into donor cells to carry out somatic cell cloning and embryo transferring, so that the obtained APN gene edited cloning pig has ability of resisting piglet diarrhea. According to the preparation method of the piglet diarrhea resistant pig provided by the invention, a receptor of a virus causing the piglet diarrhea is destroyed, any other exogenous genes cannot be introduced except edition of a targeted gene APN, non-speciality edition on a non-APN gene area on a gene group cannot be carried out, a genetic background is clean and clear, and a late safety assessment work of transgenesis is greatly reduced.

The intervertebral disc is avascular. With aging, endplates become occluded by calcified layers, and diffusion of nutrients and oxygen into the disc diminishes. The disc degenerates, and pain ensues. Conduits are delivered and deployed into the intervertebral disc to reestablish the exchange of nutrients and waste between the disc and bodily circulation to stop or reverse disc degeneration and relieve pain. The intervertebral disc installed with semi-permeable conduits may be used as an immuno-isolated capsule to encapsulate donor cells capable of biosynthesizing therapeutic molecules. The semi-permeable conduits establish the exchange of nutrients and therapeutic molecules between disc and bodily circulation to treat a disease without using immunosuppressive drugs.

The invention provides application of a Trim63 gene in preparation of a high muscle content and hypertrophic cardiomyopathy model cloned pig. Somatic cells of the Trim63 gene of a modified pig are utilized as nuclear transfer donor cells, oocytes are utilized as nuclear transfer recipient cells, and a cloned embryo is obtained through the somatic cell nuclear transfer technology. The cloned embryo is transferred into a pig uterus to gestate to obtain the Trim63 gene modified high muscle content and hypertrophic cardiomyopathy model cloned pig, artificial intervention methods, such as operation and so on for the cloned pig are not needed any more, and the efficiency of establishment of a disease model is improved. According to the high muscle content and hypertrophic cardiomyopathy model cloned pig, paired Cas9n targeting vectors are utilized for the first time to perform gene editing for large animals. The method is low in cost, sharply shortens the time for obtaining a homozygote pig and lays a foundation for gene function research and the disease model establishment for the large animals by utilizing the CRISPR/Cas9 technology.

The invention provides methods for cloning mammals that allow the donor chromosomes or donor cells to be reprogrammed prior to insertion into an enucleated oocyte. The invention also features methods of inserting chromosomes or nuclei into recipient cells.

The invention provides a production method for Fbxo40 gene knockout pigs. The production method comprises the steps that a CRISPR-Cas9 targeting vector and a PGK-Neo resistant gene are jointly transfected into a porcine embryonic fibroblast to obtain a G418-resistant positive monoclonal cell, an Fbxo40 gene in the positive monoclonal cell generates insertion or deletion mutation, a reading frame generates frame shift and stops in advance, then the obtained cell is cloned to serve as a donor cell for nuclear transfer, and an oocyte serves as a receptor oocyte for nuclear transfer; cloned embryos are obtained through a somatic cell nuclear transfer technique, the high-quality cloned embryos are transferred into the fallopian tube of an oestrous sow, and the Fbxo40 gene knockout pigs are obtained through whole-period development. According to the production method, the Fbxo40 knockout pigs are efficiently obtained through a CRISPR-Cas9 gene editing technique at the low cost, and animal models are supplied to research of muscle development and diseases related to the muscles.

Genetically engineered cells are provided which can serve as universal donor cells in such applications as reconstruction of vascular linings or the administration of therapeutic agents. The cells include a coding region which provides protection against complement-based lysis, i.e., hyperacute rejection. In addition, the cell's natural genome is changed so that functional proteins encoded by either the class II or both the class I and the class II major histocompatibility complex genes do not appear on the cell's surface. In this way, attack by T-cells is avoided. Optionally, the cells can include a self-destruction mechanism so that they can be removed from the host when no longer needed.

The present disclosure relates to methods to deconvolute a mixture sample of genetic material from different origins or sources. The disclosed methods can be used in various applications, including, the non-invasive determination of a fetal genome, a fetal -ome (e.g. exome). or other targeted fetal locus from cell-free nucleic acids in maternal plasma or other body fluids; the de-termination of cancer-associated mutations from cell-free nucleic acids in a body fluid sample that contains a mixture of nucleic acids from normal cells and tumor cells; and quantification of donor cell contamination using a body fluid from a transplantation recipient to monitor and/or predict the outcome of a transplantation procedure.

The invention provides a specific protocol for use in grafting donor cells genetically modified to produce nerve growth factors into grafting sites within the cholinergic basal forebrain and is especially useful in treating neurodegenerative conditions such as Alzheimer's Disease. Grafting sites are selected for proximity to previously identified defective, diseased or damaged brain cells. Each graft is situated no more than about 550 mum from a targeted cell and no more than about 5 mm from another graft. Depending on the size of the region to be treated, the number of grafting sites will vary upwards of 10 sites, with between 5 and 10 sites serving to deliver a therapeutically significant dosage of nerve growth factors to targeted cells. Donor cells are delivered in a composition concentration of at least 1x105 cells/mul, wherein each graft is comprised of between 2 and 20 mul of the donor cell composition. The composition is delivered to each grafting site over a period of about 5-10 minutes.

An improved method of nuclear transfer involving the transplantation of differentiated donor cell nuclei into enucleated oocytes of a species different from the donor cell is provided. The resultant nuclear transfer units are useful for the production of isogenic embryonic stem cells, in particular human isogenic embryonic or stem cells. These embryonic or stem-like cells are useful for producing desired differentiated cells and for introduction, removal or modification, of desired genes, e.g., at specific sites of the genome of such cells by homologous recombination. These cells, which may contain a heterologous gene, are especially useful in cell transplantation therapies and for in vitro study of cell differentiation. Also, methods for improving nuclear transfer efficiency by genetically altering donor cells to inhibit apoptosis, select for a specific cell cycle and/or enhance embryonic growth and development are provided.

A mobile communication system capable of preventing interference in a communication system as well as reducing the load of a user equipment in a search operation. In the mobile communication system, radio communication is performed using a carrier having the same frequency in a direct link between a donor cell and a user equipment being served thereby and an access link between a relay node and a user equipment being served thereby. In a backhaul link between the donor cell and the relay node, radio communication is performed using a carrier having a different frequency from that of the carrier used in the direct link and the access link.

The embodiment of the invention discloses a method, system and equipment of selecting a target cell, which relates to the technical field of wireless communication and is used for solving the problem that a donor base station selects the target cell to which the relay node is not allowed to access for the relay node, so as to cause failed switch. In the invention, operation and maintenance (OAM) equipment allocates the donor attribute information of the base station to the base station; the base station sends the obtained donor attribute information to other base stations adjacent to the basestation; and the donor base station determines a donor cell to which the relay node is allowed to access according to the received donor attribute information and sends the information of the determined donor cell to the relay node, the relay node only reports the measurement information of the donor cell, and the donor base station selects the target cell performing cell switch for the relay node according to the measurement information reported by the relay node. According to the invention, the problem that the donor base station selects the target cell to which the relay node is not allowed to access for the relay node so as to cause the failed switch is avoided.